Viral therapy of cancer [[electronic resource] /] / editors, Kevin J. Harrington, Richard G. Vile, Hardev S. Pandha

• Record Nr.: UNINA9910144698803321
• Pubbl/distr/stampa: Chichester, England ; ; Hoboken, NJ, : John Wiley & Sons, c2008
• ISBN: 1-282-35017-X; 9786612350177; 0-470-98579-8; 0-470-98578-X
• Descrizione fisica: 1 online resource (426 p.)
• Altri autori (Persone): HarringtonKevin J. <1958->; PandhaHardev; VileRichard G
• Disciplina: 616.99/406; 616.99406
• Soggetti: Viruses - Therapeutic use; Cancer - Treatment
• Lingua di pubblicazione: Inglese
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Note generali: Description based upon print version of record.
• Nota di bibliografia: Includes bibliographical references and index.
• Nota di contenuto: Viral Therapy of Cancer; Contents; Foreword; Preface; Contributors; 1 Adenoviruses; 1.1 Introduction; 1.2 Viral structure and life cycle; 1.3 Adenoviral vectors; 1.4 Targeting adenoviral vectors; 1.5 Clinical applications of adenoviral gene therapy; 1.6 Adenoviral vectors for immunotherapy; 1.7 Adenoviral vectors for suicide gene therapy; 1.8 Adenoviral vectors for gene replacement therapy; 1.9 Oncolytic adenoviral therapy; 1.10 Adverse outcomes of adenoviral gene therapy; 1.11 Summary; References; 2 Application of HSV-1 vectors to the treatment of cancer; 2.1 Introduction; 2.2 Basic biology of HSV2.3 Replication competent or oncolytic vectors; 2.4 Replication defective vectors; 2.5 Amplicons; 2.6 Impediments to the efficacy of HSV vectors for cancer gene therapy; 2.7 Strategies to enhance the efficacy and specificity of HSV vectors for cancer gene therapy; 2.8 Summary and conclusions; Acknowledgements; References; 3 Adeno-associated virus; 3.1 Introduction; 3.2 Biology and life cycle of AAV; 3.3 AAV serotypes; 3.4 Production of recombinant ; AAV; 3.5 Gene therapy for cancer treatment; 3.6 Anti-oncogenic properties of AAV; 3.7 Molecular chemotherapy studies with rAAV3.8 AAV-mediated sustained transgene expression as a potential cancer gene therapy strategy; 3.9 rAAV vectors have advantages in stimulating T helper 1/cytotoxic T lymphocyte responses; 3.10 rAAV vectors can be used to initiate immune responses; 3.11 Altering AAV tropism for tumour-specific delivery; 3.12 Clinical trials involving rAAV; 3.13 Conclusion; Acknowledgements; References; 4 Retroviruses; 4.1 Introduction; 4.2 Structure of retroviral particles; 4.3 Retroviral genome; 4.4 Retroviral life cycle; 4.5 Retroviral vectors; 4.6 Safety of retroviral vectors: insertional mutagenesis4.7 Gene therapy of X-linked SCID; 4.8 Retroviral cancer gene therapy; 4.9 Immunomodulatory approaches; 4.10 Conclusions; References; 5 Lentiviral vectors for cancer gene therapy; 5.1 Development of lentiviral vectors (LV); 5.2 Targeting of transgene expression; 5.3 Host immune responses to LV and their transgene; 5.4 Transgenesis; 5.5 Haematopoietic stem cell gene transfer; 5.6 Cancer treatment by LV; 5.7 Approved clinical trials using LV; 5.8 Conclusions; References; 6 Poxviruses as immunomodulatory cancer therapeutics; 6.1 Introduction6.2 General features of poxvirus structure and biology; 6.3 Clinically applicable poxviruses; 6.4 Poxviruses as potential cancer therapeutics; 6.5 Clinical experience with poxviruses; 6.6 Conclusions; References; 7 Oncolytic herpes simplex viruses; 7.1 Introduction; 7.2 Herpes simplex virology; 7.3 Properties of HSV relevant to oncolytic virus therapy; 7.4 Mutations giving tumour-selective replication; 7.5 Oncolytic HSV expressing fusogenic membrane glycoproteins (FMG); 7.6 Prodrug activation therapy and oncolytic HSV; 7.7 Combination of oncolytic HSV with immunomodulatory gene expression
• Sommario/riassunto: In the last decade there has been an explosion of interest in viral therapies for cancer. Viral agents have been developed that are harmless to normal tissues but selectively able to kill cancer cells. These agents have been endowed with additional selectivity and potency through genetic manipulation. Increasingly these viruses are undergoing evaluation in clinical trials, both as single agents and in combination with standard chemotherapy and radiotherapy. This book provides a comprehensive yet succinct overview of the current status of viral therapy of cancer. Chapters coherently present